P0211 Eversun: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (Anzup Trial 0901)
Davis, I.D.; Long, A.; Martin, A.; Espinoza, D.; Yip, S.; Thompson, J.F.; Kichenadasse, G.; Harrison, M.; Lowenthal, R.M.; Pavlakis, N.; Azad, A.; Kannourakis, G.; Steer, C.; Goldstein, D.; Shapiro, J.
European Journal of Cancer 50: e68-e69
2014
ISSN/ISBN: 0959-8049 DOI: 10.1016/j.ejca.2014.03.255
Accession: 066952102
PDF emailed within 0-6 h: $19.90
Related References
Davis, I.D.; Long, A.; Yip, S.; Espinoza, D.; Thompson, J.F.; Kichenadasse, G.; Harrison, M.; Lowenthal, R.M.; Pavlakis, N.; Azad, A.; Kannourakis, G.; Steer, C.; Goldstein, D.; Shapiro, J.; Harvie, R.; Jovanovic, L.; Hudson, A.L.; Nelson, C.C.; Stockler, M.R.; Martin, A. 2015: EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma Annals of Oncology: Official Journal of the European Society for Medical Oncology 26(6): 1118-1123Davis, I.D.; Long, A.; Yip, S.; Espinoza, D.; Thompson, J.F.; Kichenadasse, G.; Harrison, M.; Lowenthal, R.M.; Pavlakis, N.; Azad, A.; Kannourakis, G.; Steer, C.; Goldstein, D.; Shapiro, J.; Harvie, R.; Jovanovic, L.; Hudson, A.L.; Nelson, C.C.; Stockler, M.R.; Martin, A. 2015: EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma Annals of Oncology: Official Journal of the European Society for Medical Oncology 26(6): 1118-1123
Motzer, R.J.; Barrios, C.H.; Kim, T.M.; Falcon, S.; Cosgriff, T.; Harker, W.G.; Srimuninnimit, V.; Pittman, K.; Sabbatini, R.; Rha, S.Y.; Flaig, T.W.; Page, R.; Bavbek, S.; Beck, J.T.; Patel, P.; Cheung, F.-Y.; Yadav, S.; Schiff, E.M.; Wang, X.; Niolat, J.; Sellami, D.; Anak, O.; Knox, J.J. 2014: Phase Ii randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32(25): 2765-2772
Rini, B.I.; Stenzl, A.; Zdrojowy, R.; Kogan, M.; Shkolnik, M.; Oudard, S.; Weikert, S.; Bracarda, S.; Crabb, S.J.; Bedke, J.; Ludwig, J.; Maurer, D.; Mendrzyk, R.; Wagner, C.; Mahr, A.; Fritsche, J.; Weinschenk, T.; Walter, S.; Kirner, A.; Singh-Jasuja, H.; Reinhardt, C.; Eisen, T. 2016: IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial LANCET. Oncology 17(11): 1599-1611
Motzer, R.J.; Hutson, T.E.; Olsen, M.R.; Hudes, G.R.; Burke, J.M.; Edenfield, W.J.; Wilding, G.; Agarwal, N.; Thompson, J.A.; Cella, D.; Bello, A.; Korytowsky, B.; Yuan, J.; Valota, O.; Martell, B.; Hariharan, S.; Figlin, R.A. 2012: Randomized phase Ii trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30(12): 1371-1377
Molina, A.M.; Feldman, D.R.; Voss, M.H.; Ginsberg, M.S.; Baum, M.S.; Brocks, D.R.; Fischer, P.M.; Trinos, M.J.; Patil, S.; Motzer, R.J. 2012: Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Cancer 118(7): 1868-1876
Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; Uemura, H.; Motzer, R.; Fujii, Y.; Kamei, Y.; Oya, M. 2019: Randomized phase IIi trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis Annals of Oncology 30: V386-V387
Hsieh, J.J.; Chen, D.; Wang, P.I.; Marker, M.; Redzematovic, A.; Chen, Y.-B.; Selcuklu, S.D.; Weinhold, N.; Bouvier, N.; Huberman, K.H.; Bhanot, U.; Chevinsky, M.S.; Patel, P.; Pinciroli, P.; Won, H.H.; You, D.; Viale, A.; Lee, W.; Hakimi, A.A.; Berger, M.F.; Socci, N.D.; Cheng, E.H.; Knox, J.; Voss, M.H.; Voi, M.; Motzer, R.J. 2017: Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma European Urology 71(3): 405-414
Albiges, L.; Rini, B.; Haanen, J B A G.; Motzer, R.; Kollmannsberger, C.; Negrier, S.; Nole, F.; Bedke, J.; Bilen, M.; Nathan, P.; Tomita, Y.; Huang, B.; Ching, K.; Chudnovsky, A.; Robbins, P.; di Pietro, A.; Thomaidou, D.; Choueiri, T. 2019: Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (u CN): Subgroup analysis from the phase IIi JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (a RCC) Annals of Oncology 30: V359-V360
Albiges, L.; Tannir, N.M.; Burotto, M.; McDermott, D.; Plimack, E.R.; Barthélémy, P.; Porta, C.; Powles, T.; Donskov, F.; George, S.; Kollmannsberger, C.K.; Gurney, H.; Grimm, M.-O.; Tomita, Y.; Castellano, D.; Rini, B.I.; Choueiri, T.K.; Saggi, S.S.; McHenry, M.B.; Motzer, R.J. 2020: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase IIi CheckMate 214 trial Esmo Open 5(6): E001079
Choueiri, T.; Porta, C.; Suárez, C.; Hainsworth, J.; Voog, E.; Duran, I.; Reeves, J.; Czaykowski, P.; Castellano, D.; Chen, J.; Sedarati, F.; Powles, T. 2022: Randomized Phase Ii Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients with Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy Oncologist 36(9): 567-573
Choueiri, T.K.; Porta, C.; Suárez, C.; Hainsworth, J.; Voog, E.; Duran, I.; Reeves, J.; Czaykowski, P.; Castellano, D.; Chen, J.; Sedarati, F.; Powles, T. 2022: Randomized Phase Ii Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients with Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy Oncologist 27(12): 1048-1057
Feldman, D.R.; Ged, Y.; Lee, C-Han.; Knezevic, A.; Molina, A.M.; Chen, Y-Bei.; Chaim, J.; Coskey, D.T.; Murray, S.; Tickoo, S.K.; Reuter, V.E.; Patil, S.; Xiao, H.; Aghalar, J.; Apollo, A.J.; Carlo, M.I.; Motzer, R.J.; Voss, M.H. 2020: Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial Cancer 126(24): 5247-5255
Feldman, D.R.; Ged, Y.; Lee, C.-H.; Knezevic, A.; Molina, A.M.; Chen, Y.-B.; Chaim, J.; Coskey, D.T.; Murray, S.; Tickoo, S.K.; Reuter, V.E.; Patil, S.; Xiao, H.; Aghalar, J.; Apollo, A.J.; Carlo, M.I.; Motzer, R.J.; Voss, M.H. 2020: Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase Ii trial Cancer 126(24): 5247-5255
Hainsworth, J.D.; Rubin, M.S.; Arrowsmith, E.R.; Khatcheressian, J.; Crane, E.J.; Franco, L.A. 2013: Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase Ii Trial Clinical Genitourinary Cancer 11(3): 270-275
Hutson, T.E.; Escudier, B.; Esteban, E.; Bjarnason, G.A.; Lim, H.Y.; Pittman, K.B.; Senico, P.; Niethammer, A.; Lu, D.R.; Hariharan, S.; Motzer, R.J. 2014: Randomized phase IIi trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32(8): 760-767
Bjarnason, G.A.; Knox, J.J.; Kollmannsberger, C.K.; Soulieres, D.; Ernst, D.S.; Zalewski, P.; Canil, C.M.; Winquist, E.; Hotte, S.J.; North, S.A.; Heng, D.Y.C.; Macfarlane, R.J.; Venner, P.M.; Kapoor, A.; Hansen, A.R.; Eigl, B.J.; Czaykowski, P.; Boyd, B.; Wang, L.; Basappa, N.S. 2019: The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: a phase 2 clinical trial European Journal of Cancer 108: 69-77
Voss, M.H.; Chen, D.; Marker, M.; Hakimi, A.Ari.; Lee, C-Han.; Hsieh, J.J.; Knox, J.J.; Voi, M.; Motzer, R.J. 2016: Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma British Journal of Cancer 114(6): 642-649
Powles, T.; Motzer, R.J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S.Young.; Park, S.Hoon.; Geertsen, P.F.; Gross-Goupil, M.; Grande, E.; Suarez, C.; Markby, D.W.; Arroyo, A.; Dean, M.; Choueiri, T.K.; George, D. 2018: Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma British Journal of Cancer 119(6): 663-669
Rexer, H.; Bedke, J. 2017: First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO Der Urologe. Ausg. a 56(3): 385-386